This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Raymond James analyst Christopher Raymond initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Strong Buy rating and announced a price target of $46. Alumis shares closed at $28.10 on Tuesday. See how other analysts view this stock.
• B of A Securities analyst Jason Zemansky initiated coverage on Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and announced a price target of $244. Ligand Pharmaceuticals shares closed at $212.29 on Tuesday. See how other analysts view this stock.
• Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Satellos Bioscience Inc (NASDAQ:MSLE) with an Overweight rating. Satellos Bioscience shares closed at $9.54 on Tuesday. See how other analysts view this stock.
• Oppenheimer analyst Leland Gershell initiated coverage on Ocugen Inc (NASDAQ:OCGN) with an Outperform rating and announced a price target of $10. Ocugen shares closed at $1.77 on Tuesday. See how other analysts view this stock.

Considering buying LGND stock? Here’s what analysts think:

Photo via Shutterstock